Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 424 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Treatment Strategy for ecDNA-Driven Tumors Shows Potential December 5, 2024 Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer? August 20, 2024 Nurse Who Battled Cancer While In School Surprises Her Dad With... March 1, 2021 Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint... December 9, 2020 Load more HOT NEWS Drug Combination May Target the Unique Metabolism of Leukemia Stem Cells Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline Lack of Evidence for the Use of Telemedicine in the Prevention... ViPOR Regimen Associated with Durable Remissions in Patients with Specific Molecular...
